SAN FRANCISCO, May 11, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that in vitro and in vivo data from two studies support QED’s plans to evaluate a low dose of infigratinib as a treatment option for children with achondroplasia, the most common cause of disproportionate short stature.

As more cases of COVID-19 are confirmed, we recognize the increased challenges and concerns faced by participants in the BioMarin clinical studies. The safety and well-being of study participants, healthcareproviders, and our communities is paramount as the ongoing COVID-19 pandemic impacts the health and livelihoods of many worldwide. BioMarin Pharmaceutical,


QED COVID-19 Update


Dear Chandler Project, We at QED know that this is a challenging time for all families. We hope that you are all doing well, are safe, and are using this time to ensure the safety and well-being of your loved ones.  We are actively assessing the impact that COVID-19 may

This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol QBGJ398-001) for